David Francis's Insider Trades & SAST Disclosures
David Francis's most recent trade in Investors Title Co. was a trade of 145 Common Stock done at an average price of $188.7 . Disclosure was reported to the exchange on March 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David Francis.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Investors Title Co. | David L. Francis | Director | Grant, award, or other acquisition of securities at price $ 188.71 per share. | 06 Mar 2025 | 145 | 7,616 (0%) | 0% | 188.7 | 27,363 | Common Stock |
| Investors Title Co. | David L. Francis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 145 | 0 | - | - | Stock Appreciation Right | |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 643,208 | 1,217,287 | - | 0 | Common Stock | |
| Proassurance Corporation | David Francis Robert | Pres Healthcare Pro. Liability | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 17,668 | 17,668 | - | - | Restricted Stock Unit | |
| Proassurance Corporation | Robert Francis David | Pres Healthcare Pro. Liability | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2025 | 7,771 | 0 | - | - | Restricted Stock Units | |
| Proassurance Corporation | Francis David Robert | Pres Healthcare Pro. Liability | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.13 per share. | 25 Feb 2025 | 7,771 | 17,394 (0%) | 0% | 16.1 | 125,346 | Common Stock |
| Proassurance Corporation | Robert Francis David | Pres Healthcare Pro. Liability | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.13 per share. | 25 Feb 2025 | 4,647 | 15,973 (0%) | 0% | 16.1 | 74,956 | Common Stock |
| Proassurance Corporation | Francis Robert David | Pres Healthcare Pro. Liability | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.32 per share. | 25 Feb 2025 | 3,226 | 20,620 (0%) | 0% | 16.3 | 52,648 | Common Stock |
| Proassurance Corporation | Robert Francis David | Pres Healthcare Pro. Liability | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2025 | 3,226 | 0 | - | - | Restricted Share Units | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 170,841 | 170,841 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 165,156 | 559,095 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 19,528 | 397,703 (0%) | 0% | 3.7 | 72,254 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 11,765 | 417,231 (0%) | 0% | 3.7 | 43,531 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 2,960 | 394,743 (0%) | 0% | 3.7 | 10,952 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 804 | 393,939 (0%) | 0% | 3.7 | 2,975 | Class A Common Stock |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2024 | 500,000 | 1,500,000 | - | - | Series A Convertible Preferred Stock | |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 1,000,000 | 1,000,000 | - | - | Series A Convertible Preferred Stock | |
| Proassurance Corporation | Robert David Francis | Pres Healthcare Pro. Liability | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 26,294 | 26,294 | - | - | Restricted Stock Units | |
| Investors Title Co. | David L. Francis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 750 | 0 | - | - | Stock Appreciation Right | |
| Proassurance Corporation | Robert David Francis | Pres Healthcare Pro. Liability | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 7,111 | 0 | - | - | Restricted Stock Units | |
| Proassurance Corporation | Robert David Francis | Pres Healthcare Pro. Liability | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.36 per share. | 06 Mar 2024 | 7,111 | 10,780 (0%) | 0% | 12.4 | 87,892 | Common Stock |
| Proassurance Corporation | Robert David Francis | Pres Healthcare Pro. Liability | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.36 per share. | 06 Mar 2024 | 4,383 | 9,623 (0%) | 0% | 12.4 | 54,174 | Common Stock |
| Proassurance Corporation | Robert David Francis | Pres Healthcare Pro. Liability | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 3,226 | 0 | - | - | Restricted Stock Units | |
| Proassurance Corporation | Robert David Francis | Pres Healthcare Pro. Liability | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.36 per share. | 06 Mar 2024 | 3,226 | 14,006 (0%) | 0% | 12.4 | 39,873 | Common Stock |
| Organogenesis Holdings Inc... | Francisco David C. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 289,915 | 289,915 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | C. Francisco David | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 160,350 | 428,996 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | Francisco David C. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.68 per share. | 15 Feb 2024 | 18,966 | 272,963 (0%) | 0% | 3.7 | 69,795 | Class A Common Stock |
| Organogenesis Holdings Inc... | Francisco C. David | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.68 per share. | 15 Feb 2024 | 3,513 | 269,450 (0%) | 0% | 3.7 | 12,928 | Class A Common Stock |
| Organogenesis Holdings Inc... | C. David Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.48 per share. | 15 Feb 2024 | 804 | 268,646 (0%) | 0% | 3.5 | 2,798 | Class A Common Stock |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2023 | 113 | 32,799 | - | - | Dividend Equivalent Rights | |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 112 | 32,667 | - | - | Dividend Equivalent Rights | |
| Investors Title Co. | David L. Francis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 750 | 0 | - | - | Stock Appreciation Right | |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.37 per share. | 15 May 2023 | 250,000 | 3,849,224 | - | 0.4 | 92,500 | Common Stock |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.51 per share. | 15 May 2023 | 211,000 | 4,060,224 | - | 0.5 | 107,610 | Common Stock |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.32 per share. | 15 May 2023 | 154,645 | 3,599,224 | - | 0.3 | 49,486 | Common Stock |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 2,500,000 | 2,500,000 | - | - | Employee stock option (right to buy) | |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.11 per share. | 07 Mar 2023 | 30,909 | 3,385,301 | - | 1.1 | 34,216 | Common Stock |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.09 per share. | 07 Mar 2023 | 29,999 | 3,415,300 | - | 1.1 | 32,819 | Common Stock |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.07 per share. | 07 Mar 2023 | 29,279 | 3,444,579 | - | 1.1 | 31,270 | Common Stock |
| Investors Title Co. | David L. Francis | Director | Grant, award, or other acquisition of securities at price $ 93.87 per share. | 01 Mar 2023 | 319 | 7,471 (0%) | 0% | 93.9 | 29,945 | Common Stock |
| Investors Title Co. | David L. Francis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 319 | 0 | - | - | Stock Appreciation Right | |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 110 | 32,554 | - | - | Dividend Equivalent Rights | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 287,892 | 287,892 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 242,508 | 291,929 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.92 per share. | 15 Feb 2023 | 3,506 | 50,374 (0%) | 0% | 2.9 | 10,238 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.75 per share. | 15 Feb 2023 | 953 | 49,421 (0%) | 0% | 2.8 | 2,621 | Class A Common Stock |
| Maximus Inc. | David R. Francis | General Counsel | Sale of securities on an exchange or to another person at price $ 74.68 per share. | 04 Jan 2023 | 3,632 | 10,025 (0%) | 0% | 74.7 | 271,238 | Common Stock |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 5,880 | 3,356,892 | - | 0 | Common Stock | |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 5,000 | 3,362,772 | - | 0 | Common Stock | |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 2,500 | 3,354,392 | - | 0 | Common Stock | |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2022 | 4,728,634 | 0 | - | - | Employee stock option (right to buy) | |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 4,728,634 | 4,728,634 | - | - | Employee stock option (right to buy) | |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2022 | 91 | 23,102 | - | - | Dividend Equivalent Rights | |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Nov 2022 | 5,506 | 5,506 | - | - | Common Stock | |
| Maximus Inc. | David R. Francis | General Counsel | Sale of securities on an exchange or to another person at price $ 70.92 per share. | 23 Nov 2022 | 1,800 | 13,657 (0%) | 0% | 70.9 | 127,656 | Common Stock |
| Maximus Inc. | David R. Francis | General Counsel | Sale of securities on an exchange or to another person at price $ 57.87 per share. | 30 Sep 2022 | 5,326 | 15,457 (0%) | 0% | 57.9 | 308,216 | Common Stock |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 155 | 33,769 | - | - | Dividend Equivalent Rights | |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2022 | 144 | 33,614 | - | - | Dividend Equivalent Rights | |
| Investors Title Co. | David L. Francis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 750 | 0 | - | - | Stock Appreciation Right | |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2022 | 9,299,998 | 9,299,998 | - | - | Restricted Stock Units | |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 118 | 33,469 | - | - | Dividend Equivalent Rights | |
| Investors Title Co. | David L. Francis | Director | Grant, award, or other acquisition of securities at price $ 73.00 per share. | 16 Feb 2022 | 478 | 7,152 (0%) | 0% | 73 | 34,894 | Common Stock |
| Investors Title Co. | David L. Francis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2022 | 478 | 0 | - | - | Stock Appreciation Right | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 95,692 | 95,692 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 40,348 | 56,709 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.03 per share. | 15 Feb 2022 | 1,876 | 54,833 (0%) | 0% | 8.0 | 15,064 | Class A Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 15 Feb 2022 | 953 | 53,880 (0%) | 0% | 7.8 | 7,414 | Class A Common Stock |
| Sonder Holdings Inc - Ordi... | Francis Davidson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.20 per share. | 21 Jan 2022 | 1,829,268 | 3,367,772 | - | 8.2 | 14,999,998 | Common Stock |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 85 | 23,250 | - | - | Dividend Equivalent Rights | |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2021 | 4,613 | 4,613 | - | - | Common Stock | |
| Maximus Inc. | David R. Francis | General Counsel | Sale of securities on an exchange or to another person at price $ 83.20 per share. | 30 Sep 2021 | 5,788 | 16,213 (0%) | 0% | 83.2 | 481,562 | Common Stock |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2021 | 112 | 35,141 | - | - | Dividend Equivalent Rights | |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 105 | 35,029 | - | - | Dividend Equivalent Rights | |
| Investors Title Co. | David L. Francis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 750 | 0 | - | - | Stock Appreciation Right | |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 119 | 34,923 | - | - | Dividend Equivalent Rights | |
| Investors Title Co. | David L. Francis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 434 | 0 | - | - | Stock Appreciation Right | |
| Investors Title Co. | David L. Francis | Director | Grant, award, or other acquisition of securities at price $ 68.70 per share. | 18 Feb 2021 | 434 | 6,674 (0%) | 0% | 68.7 | 29,816 | Common Stock |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 83,955 | 83,955 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 10,965 | 16,361 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2021 | 43,239 | 43,239 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc... | David C. Francisco | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2021 | 5,396 | 5,396 (0%) | 0% | 0 | Class A Common Stock | |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2020 | 94 | 29,617 | - | - | Dividend Equivalent Rights | |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2020 | 5,186 | 5,186 | - | - | Common Stock | |
| Maximus Inc. | David R. Francis | General Counsel | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 06 Oct 2020 | 6,677 | 10,024 (0%) | 0% | 70 | 467,390 | Common Stock |
| Maximus Inc. | David R. Francis | General Counsel | Sale of securities on an exchange or to another person at price $ 68.41 per share. | 30 Sep 2020 | 6,246 | 16,701 (0%) | 0% | 68.4 | 427,289 | Common Stock |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2020 | 134 | 37,262 | - | - | Dividend Equivalent Rights | |
| SINTX Technologies Inc | David Francis O’Brien | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 25 Aug 2020 | 5,477 | 5,477 (0%) | 0% | 1.8 | 9,585 | Common Stock |
| SINTX Technologies Inc | David Francis O’Brien | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 1.52 per share. | 25 Aug 2020 | 269 | 5,746 (0%) | 0% | 1.5 | 409 | Common Stock |
| eHealth Inc | David Francis | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.86 per share. | 29 Jul 2020 | 336 | 209,995 (0%) | 0% | 69.9 | 23,473 | Common Stock |
| eHealth Inc | David Francis | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.98 per share. | 10 Jul 2020 | 7,740 | 210,331 (0%) | 0% | 111.0 | 858,985 | Common Stock |
| eHealth Inc | David Francis | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.98 per share. | 10 Jul 2020 | 272 | 218,071 (0%) | 0% | 111.0 | 30,187 | Common Stock |
| eHealth Inc | David Francis | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.28 per share. | 28 Jun 2020 | 272 | 218,343 (0%) | 0% | 91.3 | 24,828 | Common Stock |
| eHealth Inc | David Francis | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 131.50 per share. | 02 Jun 2020 | 16,874 | 220,787 (0%) | 0% | 131.5 | 2,218,931 | Common Stock |
| eHealth Inc | David Francis | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 130.64 per share. | 02 Jun 2020 | 5,954 | 237,661 (1%) | 0% | 130.6 | 777,831 | Common Stock |
| eHealth Inc | David Francis | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 132.17 per share. | 02 Jun 2020 | 2,172 | 218,615 (0%) | 0% | 132.2 | 287,073 | Common Stock |
| Maximus Inc. | David R. Francis | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2020 | 143 | 37,128 | - | - | Dividend Equivalent Rights | |
| Investors Title Co. | David L. Francis | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2020 | 750 | 0 | - | - | Stock Appreciation Right |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges